Publications

22 Feb 2021
Working Paper Summaries

Private and Social Returns to R&D: Drug Development and Demographics

Keywords: by Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger; Pharmaceutical

1994
Article

The Evolution of Integrative Capability: Innovation in Cardiovascular Drug Discovery

By: Rebecca M. Henderson

Keywords: Innovation and Invention; Health; Integration

12 Dec 2022
News

Buy-In from Black Patients Suffers When Drug Trials Don’t Include Them

08 Aug 2023
News

The Weight-Loss Drug Frenzy Is Outrunning the Company Behind It

08 Jul 2019
News

What the U.S. can learn from Germany on drug prices

February 26, 2003
Article

Consumers' Reports on the Health Effects of Direct-To-Consumer Drug Advertising

By: Joel S. Weissman, David Blumenthal, Alvin J. Silk, Kinga Zapert, Michael Newman and Robert Leitman

Keywords: Customers; Advertising; Health; Pharmaceutical Industry

June 2020
Case

Breakthroughs at Blueprint Medicines

By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma

Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details

Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts

Educators

14 Sep 2017
News

Insurers cutting back on drug coupons amid concerns over consumer costs

November 2019
Case

The Genesis Lab at Novartis

By: Amy C. Edmondson, Ranjay Gulati, Patrick J. Healy and Kerry Herman

Novartis' Genesis Labs program, launched in 2016 as part of Novartis Institutes for Biomedical Research (NIBR), hosted pitch competitions where teams of NIBR scientists proposed ideas to explore that aimed to revolutionize drug discovery. The goal was to break down... View Details

Keywords: Drug Discovery; Health Care and Treatment; Research and Development; Innovation and Invention; Programs; Management

Educators

August 2020
Article

A History of Prescription Drug Monitoring Programs in the United States: Political Appeal and Public Health Efficacy

By: A Jay Holmgren, Alyssa Botelho and Allan M Brandt

Prescription drug monitoring programs (PDMPs) have become a widely embraced policy to address the US opioid crisis. Despite mixed scientific evidence on their effectiveness at improving health and reducing overdose deaths, 49 states and Washington, DC have adopted... View Details

Keywords: Health Disorders; Information Technology; Programs; Technology Adoption; History; Government and Politics; Policy; United States

Register to Read

fall 1994
Article

Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery

By: Rebecca M. Henderson and Ian Cockburn

Keywords: Investment; Competition; Ethics; Health

2001
Working Paper

Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery

By: Stefan Thomke and Walter Kuemmerle

July 2002
Article

Asset Accumulation, Interdependence and Technological Change: Evidence from Pharmaceutical Drug Discovery

By: Stefan Thomke and Walter Kuemmerle

Keywords: Assets; Information Technology; Change; Health

Summer 2021
Article

The Cost and Evolution of Quality at Cipla Ltd, 1935–2016

By: Muhammad H. Zaman and Tarun Khanna

This article examines the evolution of Indian pharmaceutical manufacturer Cipla towards producing drugs that met the quality standards of European and U.S. regulators. It employs new research in Cipla’s corporate archives, the Creating Emerging Markets database, and... View Details

Keywords: Cipla; Pharmaceuticals; Drug Quality; Generics; Quality; Standards; Information Technology; Cost; Organizational Culture; Business History; Pharmaceutical Industry; India

February 1998 (Revised March 2003)
Teaching Note

Eli Lilly and Company: Drug Development Strategy (A) and (B) TN

By: Stefan H. Thomke and Ashok Nimgade

Teaching Note for (9-698-010) and (9-698-026). View Details

Article

Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery

By: Rebecca M. Henderson and Iain Cockburn

Keywords: Behavior; Research and Development; Organizations; Health

January–February 2021
Article

Food and Drug Administration Guidance Documents and New Medical Devices: The Case of Breast Prostheses

By: Rachel E. Weitzman, Ariel Dora Stern and Daniel B. Kramer

As pressure mounts on the Food and Drug Administration (FDA) to speed its review process for novel devices, and budgetary pressures further strain its resources, the critical role of guidance documents in assuring consistent, rigorous, and scientifically grounded... View Details

Keywords: Medical Devices; FDA; Health Care and Treatment; Government Administration; Information; Standards

04 Sep 2014
News

Our focus was to get drug companies to invest money in ALS

millions of dollars into research, and removed critical barriers to the development of treatments. “Our focus was to get drug companies to invest money in ALS,” says Kremer, who was diagnosed in 2004, just weeks into his first year at... View Details

2022
Working Paper

Causal Inference During A Pandemic: Evidence on the Effectiveness of Nebulized Ibuprofen as an Unproven Treatment for COVID-19 in Argentina

By: Sebastian Calonico, Rafael Di Tella and Juan Cruz Lopez Del Valle

Many medical decisions during the pandemic were made without the support of causal evidence obtained in clinical trials. We study the case of nebulized ibuprofen (NaIHS), a drug that was extensively used on COVID-19 patients in Argentina amidst wild claims about its... View Details

Keywords: COVID-19; Drug Treatment; Health Pandemics; Health Care and Treatment; Decision Making; Outcome or Result; Argentina